drugset / Trial / NCT02378662
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
Phase 2
Terminated
2 enrolled
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
Timeline
- Start
- 2015-04
- Primary completion
- 2016-01
- Completion
- 2016-06
Outcome
Outcome not reported
Stopped: “Sponsor's decision of the Early Termination of the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TARGTEPO | Unknown | — | — |